Abortion Drugs Market, By Drug Class (Mifepristone, Misoprostol, Pitocin, Hemabate, Carboprost), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies) – Global Forecast (2024 – 2032)

Abortion Drugs Market Size

Abortion Drugs Market was valued at around USD 24.4 billion in 2023 and is estimated to grow at a CAGR of 8.2% between 2024 and 2032. Abortion drugs, also known as medication abortion or medical abortion, refer to a non-surgical method of terminating a pregnancy using pharmaceutical drug delivery. This approach involves the use of medication rather than a surgical procedure to induce abortion.
 

As per U.S. Department of Health & Human Services, in 2020, the adolescent birth rate stood at 15.4 (births per 1,000 females aged 15-19), marking an 8% decrease from 2019. With 158,043 births among females in this age bracket, these accounted for less than five percent of all births in 2020.
 

Furthermore, as awareness about reproductive health and abortion options expand, teenagers may increasingly seek information about non-surgical methods, leading to a higher demand for abortion pills. Improved accessibility to healthcare services and information may contribute to this trend.  Thus, the abovementioned factors are anticipated to augment business expansion.
 

Abortion Drugs Market Trends

Medication abortion has gained acceptance globally as an alternative to surgical procedures. This trend is driven by the perceived safety and efficacy of these medications in terminating early pregnancies. Therefore, initiatives aimed at educating the public about reproductive health, contraceptives, and abortion options plays a crucial role. Informed decision-making is encouraged through comprehensive education, reducing the stigma associated with abortion, and fostering a better understanding of available options.
 

• Healthcare infrastructure improvements and increased awareness campaigns in developing countries have expanded access to reproductive health services, including abortion drugs. The market is witnessing growth in regions wherein such services were historically less accessible.
   
• International organizations and health initiatives focused on reproductive health and family planning contribute to the accessibility of abortion drugs. Efforts to reduce maternal mortality rates often involve making safe abortion services, including medication abortion, more widely available.
   

Abortion Drugs Market Analysis

Based on drug class, the abortion drugs industry is segmented into mifepristone, misoprostol, pitocin, hemabate, sarboprost, and other drug classes. The mifepristone segment is poised to record a CAGR of 8.6% during the forecast period.
 

• Mifepristone, often used in combination with misoprostol for medication abortion, has seen increased acceptance globally. Its efficacy and non-invasive nature contribute to its popularity as a method for terminating early pregnancies.
   
• Regulatory changes impact the availability and accessibility of mifepristone. Depending on the region, changes in regulations may either facilitate or restrict the use of mifepristone for abortion. Monitoring regulatory developments is crucial for stakeholders in the pharmaceutical and healthcare industries.
   
• Thus, aforementioned factors will promote market growth during forecast period.

The abortion drugs market by distribution channel is categorized into hospital pharmacies, retail pharmacies, and online pharmacies. The hospital pharmacies segment accounted for around USD 14.5 billion revenue size in 2023.
 

• Hospital pharmacies often play a significant role in the distribution of abortion drugs due to the need for medical supervision. The use of these drugs is typically regulated, and healthcare professionals in hospitals can ensure that the medication is administered safely and in accordance with established guidelines.
   
• Some abortion procedures, particularly those involving complications or situations wherein close medical monitoring is required, may be conducted in a hospital setting. In such cases, hospital pharmacies become a central point for the procurement and distribution of the necessary medications.
   
• In situations where abortion drugs are administered in response to emergencies or critical care scenarios, hospital pharmacies play a crucial role in ensuring timely access to the required medications. This is particularly relevant when addressing complications or situations requiring immediate medical attention.

North America abortion drugs market accounted for USD 11.1 billion revenue in 2023 and is predicted to witness substantial market growth over the analysis timeline.
 

• The availability and usage of abortion drugs, including mifepristone and misoprostol, are influenced by the legal and regulatory environment. Regulations vary among North American countries such as the U.S. and Canada, impacting the method in which these drugs are prescribed, dispensed, and administered.
   
• The COVID-19 pandemic accelerated the adoption of telemedicine services, including for reproductive healthcare. Telemedicine valued at USD 71.5 billion in 2022, have become important for consultations, prescriptions, and follow-up care related to abortion drugs, offering increased accessibility to a broader population.
   
• In the U.S., the regulations around mifepristone have been subject to changes. During the COVID-19 pandemic, the FDA temporarily eased restrictions on the dispensing of mifepristone through mail or delivery, allowing greater access, thereby boosting market growth.
   

Abortion Drugs Market Share

The abortion drugs industry is competitive in nature, with several large multinationals and small and mid-sized companies competing in the industry. The development and launch of novel advanced products based on different technologies is among a key market strategy. Some of the leading industry players including Cipla Limited, Pfizer Inc., Sun Pharmaceutical among others have a notable presence in the market.
 

Abortion Drugs Market Companies

Some of the eminent market participants operating in the abortion drugs industry include:

• Cipla Limited
• Endo International plc
• Exelgyn
• Gedeon Richter plc
• Jubilant Life Sciences
• Lupin Limited
• Mylan N.V.
• Pfizer Inc.
• Sun Pharmaceutical Industries
• Torrent Pharmaceuticals Ltd.
• Zydus Lifesciences Limited
   

Abortion Drugs Industry News

• In July 2023, Endo International plc and Premier, Inc. announced that Endo's Par Sterile Products business had supplied Pitocin vials through Premier's ProvideGx and PremierProRx programs. The partnership involved a multifaceted approach that sought to provide stable product supply through adequate safety stock on a long-term basis.
   

Abortion drugs market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD Million from 2018 - 2032 for the following segments:

Click here to Buy Section of this Report

Market, By Drug Class

• Mifepristone 
• Misoprostol 
• Pitocin
• Hemabate
• Carboprost
• Other drug classes

Market, By Distribution Channel

• Hospital pharmacies
• Retail pharmacies
• Online pharmacies

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Argentina
  • Rest of Latin America
• Middle East and Africa
  • Saudi Arabia
  • South Africa
  • UAE
  • Rest of Middle East and Africa